- US12565685utility2026Engineering AAV0 cites
- US12551575utility2026Htt Repressors and Uses Thereof0 cites
- US12509703utility2025Controlled Transgene Expression in Regulatory T Cells0 cites
- US12497632utility2025Clinical Parameters by Expression of Factor VIII0 cites
- US12318427utility2025Methods and Compositions for Modulation of Tau Proteins0 cites
- US12139517utility2024Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof0 cites
- US12043650utility2024Methods and Compositions for Modification of a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene0 cites
- US11981967utility2024Engineering AAV0 cites
- US11920169utility2024Compositions for Linking Dna-binding Domains and Cleavage Domains0 cites
- US11898158utility2024Methods and Compositions for the Treatment of Lysosomal Storage Diseases0 cites
- US11857641utility2024Method for the Treatment of Mucopolysaccharidosis Type I0 cites
- US11859190utility2024Methods and Compositions for Regulation of Transgene Expression0 cites
- US11845965utility2023Regulation of Gene Expression Using Engineered Nucleases0 cites
- US11834686utility2023Engineered Target Specific Base Editors0 cites
- US11827900utility2023Engineered Target Specific Nucleases0 cites
- US11793888utility2023Methods and Compositions for Engineering Immunity0 cites
- US11723952utility2023Methods and Compositions for Treating Huntington's Disease0 cites
- US11725192utility2023Separation and Quantification of Empty and Full Viral Capsid Particles0 cites
- US11725218utility2023Artificial Nucleases Comprising Engineered Cleavage Half-domains0 cites
- US11718834utility2023Compositions and Methods for Producing Recombinant AAV0 cites
Page 1 of 2Next →